Thanks W7s.
@RaceOncology
If we take it as given that Bisatrene works as a single agent, is there not a significant risk that it does not work when combined with other agents in trials. Due to: high cancer burden (late stage, ie not being used as a front line treatment), weakened immune system of late stage patients/chemo, unknown interactions.
Getting the best drugs to the front line seems to be an industry elephant in the room from patients point of view. Understandably difficult for ethical reasons of course, and not even broaching market power and commercial interests etc.
How we can evaluate the weight of this risk here?
Cheers. (apologies if this is already a well covered subject)
RAC Charts, page-1109
-
- There are more pages in this discussion • 633 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.020(1.29%) |
Mkt cap ! $258.9M | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.57 | $1.50 | $37.92K | 25.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7319 | $1.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.53 | 400 | 1 |
View Market Depth
| Last trade - 14.35pm 19/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |